Parkinson’s Disease Psychosis: Watchful Waiting vs Proactive Treatment (CME/CE Podcast)
Activity Description and Purpose
Hallucinations and delusions cause a significant number of hospitalizations and nursing home admissions for our patients with Parkinson’s disease. Listen to Dr Kevin Black share his approach to timely diagnosis and evidence-based management that can improve the daily lives of these patients and their caregivers.
This educational activity is intended for neurologists, psychiatrists, and primary care clinicians caring for patients with Parkinson's disease psychosis.
After completing this activity, participants will be better able to:
- Describe the evidence-based rationale for proactive screening, diagnosis, and treatment of Parkinson’s disease psychosis
- Integrate routine screening for symptoms of psychosis in Parkinson's disease into practice
Kevin Black, MD
Professor of Psychiatry, Neurology, Radiology, and Neurobiology
Washington University in St Louis School of Medicine
St Louis, Missouri
MedEdicus LLC adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to accreditation of the activity.
Kevin Black, MD, receives royalties from QuanDyn; is a consultant for SK Life Science, Inc; is on the speakers bureau for ACADIA Pharmaceuticals Inc; and is a contracted researcher for Emalex Biosciences Inc.
Jennifer Caudle, DO, has nothing to disclose.
Peer Reviewer Disclosure
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this activity for a maximum of 0.25 ANCC contact hour.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or ACADIA Pharmaceuticals Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 261.1
- 0.25 AMA PRA Category 1 Credit™
- 0.25 ANCC
- 0.25 Participation